Coya Therapeutics enrolls 100th patient in Phase 2/3 ALSTARS trial, full enrollment on track for early Q2 2027
Coya Therapeutics announced enrollment of its 100th patient in the Phase 2/3 ALSTARS trial of COYA 302 and expects full enrollment to allow topline data in early Q2 2027.Key Highlights:Original SEC Filing: Coya Therapeutics, Inc. [ COYA ] - 8-K - Sep. 15, 2026This is an AI-powered summary. It may c…